CURE biotech ETF receives investment grade rating
ETF Securities has received an “investment grade” rating for its CURE ETF from ratings firm Lonsec.
CURE began trading on the Australian Securities Exchange (ASX) in November last year and replicated the S&P Biotechnology Select Industry Index, which achieved annual growth of almost 22 per cent over the last five years.
The Lonsec product review had described the fund as: “the only ETF of its kind to provide a pure US Biotechnology thematic exposure on the ASX”. Lonsec believes the Fund provided investors with an efficient and relatively transparent means to gain an economic interest to the biotechnology market in the US.
Kris Walesby, head of ETF Securities Australia, said the Lonsec rating would provide local investors with increased confidence they had broader options than the Australian market.
“When it comes to a large universe of healthcare biotech stocks, the US is where you need to look for the best chance of ground-breaking developments and consequent investment returns,” Walesby said.
AUTHOR
Chris Dastoor
Recommended for you
The UK-based global asset manager has formed a new group executive committee to accelerate its growth strategy following the commencement of its new CEO this month.
Momentum Media has announced 26 winners across 10 individual and 15 group categories for its brand-new Australian AI Awards.
The financial services industry is currently “overwhelmed with quality and quantity of candidates”, Kaizen Recruitment explains, leading executives to face 12-month long recruitment processes.
Zenith Investment Partners has appointed an experienced research executive as its new group head of research following the departure of Bronwen Moncrieff.
